[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517994":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":50,"centralContacts":51,"locations":57,"responsibleParty":88,"collaborators":92,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":50,"eligibilityCriteria":108,"healthyVolunteers":104,"sex":109,"minAge":110,"maxAge":50,"enrollmentInfo":111,"targetDuration":50,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":50,"overallStatus":120,"whyStopped":50,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Thomas Jefferson University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (mp-MRI, Definity, mp-US, prostate biopsies)","EXPERIMENTAL","Patients undergo mp-MRI, receive Definity IV, and undergo transrectal mp-US and prostate biopsies on study.",[13,14,15,16],"Procedure: ultiparametric Magnetic Resonance Imaging","Drug: Perflutren lipid microsphere","Procedure: Transrectal Ultrasound","Procedure: Biopsy of Prostate",[18,28,35,43],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","ultiparametric Magnetic Resonance Imaging","Undergo mp-MRI",[9],[24,25,26,27],"MP-MRI","mpMRI","Multi-parametric MRI","Multiparametric MRI",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Perflutren lipid microsphere","Given IV",[9],[34],"Definity",{"type":19,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Transrectal Ultrasound","Undergo transrectal mp-US",[9],[40,41,42],"endorectal ultrasound","ERUS","TRUS",{"type":19,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"Biopsy of Prostate","Undergo prostate biopsies",[9],[48,49],"Prostate Biopsy","Prostatic Biopsy",null,[52],{"name":53,"role":54,"phone":55,"phoneExt":50,"email":56},"Flemming Forsberg, PhD","CONTACT","215-955-4870","Flemming.Forsberg@jefferson.edu",[58,73],{"facility":59,"status":50,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Sidney Kimmel Cancer Center at Thomas Jefferson University","Philadelphia","Pennsylvania","19107","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-75.16362,39.95238,{"lat":69,"lon":68},[72],{"name":53,"role":54,"phone":55,"phoneExt":50,"email":56},{"facility":74,"status":50,"city":75,"state":50,"zip":50,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Amsterdam Medical Center","Amsterdam-Zuidoost","Netherlands","NL",{"type":66,"coordinates":79},[80,81],4.97222,52.3075,{"lat":81,"lon":80},[84],{"name":85,"role":54,"phone":86,"phoneExt":50,"email":87},"Harrie Beerlage, MD","(020) 4440272","h.p.beerlage@amsterdamumc.nl",{"type":89,"investigatorFullName":90,"investigatorTitle":91,"investigatorAffiliation":5,"oldNameTitle":50,"oldOrganization":50},"PRINCIPAL_INVESTIGATOR","Flemming Forsberg","Professor - Radiology",[93,95,97,99],{"name":94,"class":6},"Amsterdam UMC, location VUmc",{"name":96,"class":6},"Eindhoven University of Technology",{"name":98,"class":6},"Eigen",{"name":100,"class":101},"GE Healthcare","INDUSTRY","100517994","phase-3-multiparametric-ultrasound-for-the-diagnosis-of-clinically-significant-prostate-cancer-100517994",false,"NCT06024772","Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer","Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)","Inclusion Criteria:\n\n* Subject must be scheduled for a prostate biopsy, based on an elevated PSA (\\> 3.0ng\u002Fml) per most recent National Comprehensive Cancer Network (NCCN) guidelines, elevated PSA velocity (\\> 0.75ng\u002Fml\u002Fyear), or abnormal digital rectal examination\n* Subject must be able and willing to give written informed consent for a contrast enhanced ultrasound study of the prostate including the additional study biopsies\n* Subject must be a male at least 18 years of age when informed consent is obtained\n\nExclusion Criteria:\n\n* Participant in a clinical trial involving an investigational drug within the past 30 days\n* Patients with known or suspected hypersensitivity to perflutren, polyethylene glycol (PEG), or any other component of Definity\n* Previous treatment for prostate cancer, including hormone therapy\n* Clinically unstable, severely ill, or moribund as per treating physician","MALE","18 Years",{"count":112,"type":113},300,"ESTIMATED","INTERVENTIONAL",[116],"PHASE3","This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.",[119],"Prostate Carcinoma","NOT_YET_RECRUITING","2026-06-03",{"date":123,"type":124},"2026-06-05","ACTUAL",{"date":126,"type":113},"2026-07",{"date":128,"type":113},"2027-02",{"name":5,"class":6},2]